![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC25A48 |
Gene summary for SLC25A48 |
![]() |
Gene information | Species | Human | Gene symbol | SLC25A48 | Gene ID | 153328 |
Gene name | solute carrier family 25 member 48 | |
Gene Alias | SLC25A48 | |
Cytomap | 5q31.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6ZT89 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153328 | SLC25A48 | P4T-E | Human | Esophagus | ESCC | 2.26e-06 | 2.06e-01 | 0.1323 |
153328 | SLC25A48 | P9T-E | Human | Esophagus | ESCC | 3.74e-03 | 4.23e-02 | 0.1131 |
153328 | SLC25A48 | P12T-E | Human | Esophagus | ESCC | 8.73e-28 | 6.22e-01 | 0.1122 |
153328 | SLC25A48 | P21T-E | Human | Esophagus | ESCC | 3.50e-02 | 8.45e-02 | 0.1617 |
153328 | SLC25A48 | P27T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.44e-01 | 0.1055 |
153328 | SLC25A48 | P48T-E | Human | Esophagus | ESCC | 9.20e-06 | 1.30e-01 | 0.0959 |
153328 | SLC25A48 | P52T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.51e-01 | 0.1555 |
153328 | SLC25A48 | P107T-E | Human | Esophagus | ESCC | 2.17e-12 | 5.23e-01 | 0.171 |
153328 | SLC25A48 | P128T-E | Human | Esophagus | ESCC | 1.42e-14 | 3.76e-01 | 0.1241 |
153328 | SLC25A48 | P130T-E | Human | Esophagus | ESCC | 9.67e-18 | 4.40e-01 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A48 | SNV | Missense_Mutation | novel | c.422N>T | p.Gly141Val | p.G141V | Q6ZT89 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
SLC25A48 | SNV | Missense_Mutation | rs755363570 | c.415N>T | p.Arg139Trp | p.R139W | Q6ZT89 | protein_coding | tolerated(0.13) | possibly_damaging(0.711) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A48 | SNV | Missense_Mutation | c.298N>T | p.Pro100Ser | p.P100S | Q6ZT89 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
SLC25A48 | SNV | Missense_Mutation | novel | c.22N>T | p.Asp8Tyr | p.D8Y | Q6ZT89 | protein_coding | deleterious(0.03) | benign(0.055) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A48 | SNV | Missense_Mutation | novel | c.52N>C | p.Ala18Pro | p.A18P | Q6ZT89 | protein_coding | tolerated(0.06) | possibly_damaging(0.847) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SLC25A48 | SNV | Missense_Mutation | rs755363570 | c.415C>T | p.Arg139Trp | p.R139W | Q6ZT89 | protein_coding | tolerated(0.13) | possibly_damaging(0.711) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC25A48 | SNV | Missense_Mutation | rs768100399 | c.422N>A | p.Gly141Glu | p.G141E | Q6ZT89 | protein_coding | tolerated(0.2) | benign(0.001) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC25A48 | SNV | Missense_Mutation | rs533785254 | c.139N>T | p.Arg47Cys | p.R47C | Q6ZT89 | protein_coding | tolerated(0.05) | possibly_damaging(0.707) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLC25A48 | SNV | Missense_Mutation | rs755363570 | c.415N>T | p.Arg139Trp | p.R139W | Q6ZT89 | protein_coding | tolerated(0.13) | possibly_damaging(0.711) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
SLC25A48 | SNV | Missense_Mutation | c.463N>A | p.Leu155Ile | p.L155I | Q6ZT89 | protein_coding | tolerated(0.3) | benign(0.043) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |